RESEARCH
ONGOING CLINICAL TRIALS
/ SECOND-LINE STUDIES
/ SECOND-LINE STUDIES
Phase I ADP-0033-001 Second line
A PHASE I OPEN LABEL, CLINICAL TRIAL EVALUATING THE SAFETY AND ANTI-TUMOR ACTIVITY OF AUTOLOGOUS T CELLS EXPRESSING ENHANCED TCRS SPECIFIC FOR ALPHA-FETOPROTEIN (AFPC332T) IN HLA-A2 POSITIVE SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
A PHASE I OPEN LABEL, CLINICAL TRIAL EVALUATING THE SAFETY AND ANTI-TUMOR ACTIVITY OF AUTOLOGOUS T CELLS EXPRESSING ENHANCED TCRS SPECIFIC FOR ALPHA-FETOPROTEIN (AFPC332T) IN HLA-A2 POSITIVE SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies
Safety, preliminary efficacy and PK of isatuximab (SAR650984) alone or in combination with atezolizumab in patients with advanced malignancies
RECRUITMENT IS CURRENTLY CLOSED
Safety, preliminary efficacy and PK of isatuximab (SAR650984) alone or in combination with atezolizumab in patients with advanced malignancies
RECRUITMENT IS CURRENTLY CLOSED